The demonstration aims to stabilize prices for enrollees while the most significant changes to the Part D program since its creation in 2006 are implemented, according to a CMS fact sheet published July 29.
In 2025, several provisions in the Inflation Reduction Act will take effect. Prescription drug costs for Medicare beneficiaries will be capped at $2,000 annually, and beneficiaries will be able to spread the costs of expensive drugs in smaller payments throughout the year.
Here are five things to know:
- Participation in the premium stabilization program is voluntary for plans. Insurers have until Aug. 5 to inform CMS if they will elect to participate.
- Plans participating in the demonstration will reduce base beneficiary premiums by $15 for 2025. If a $15 reduction results in the plan premium being less than $0, the plan will have no premium cost.
- For subsequent years, plans cannot raise premiums by more than $35.
- CMS will change risk corridors for plans participating in the demonstration. The government will take on more risk for potential losses, according to CMS’s fact sheet.
- The demonstration will last for three years. If plans do not choose to participate in 2025, they cannot participate in the demonstration in subsequent years.
Read more here.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
